Literature DB >> 3334704

Expression and characterization of hepatitis B virus precore-core antigen in E. coli.

R E Lanford1, L M Notvall, G R Dreesman, C R Harrison, D Lockwood, K H Burk.   

Abstract

The hepatitis B virus core antigen, including the precore sequence (HBcAg-p25), was expressed at very high levels in bacteria. Three expression vectors were constructed in which the synthesis of HBcAg-p25 was controlled by the tac promoter, and the number of nucleotides between the bacterial ribosome binding site and the precore initiation codon was varied in order to maximize HBcAg-p25 synthesis. The relative amount of HBcAg-p25 polypeptide expressed by the different vectors was estimated by SDS-polyacrylamide gel electrophoresis and immunoblot. HBcAg-p25 was associated with an insoluble fraction of bacterial extracts and required ionic detergents for solubilization. Comparison by ELISA of the immunoreactivity of HBcAg with and without the precore sequence suggested that human anti-HBcAg IgG preferentially recognizes HBcAg lacking the precore sequence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3334704     DOI: 10.1089/vim.1987.1.97

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  3 in total

1.  Exposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173).

Authors:  Sophie Le Pogam; Pong Kian Chua; Margaret Newman; Chiaho Shih
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein.

Authors:  S Le Pogam; T T Yuan; G K Sahu; S Chatterjee; C Shih
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system.

Authors:  R E Lanford; V Luckow; R C Kennedy; G R Dreesman; L Notvall; M D Summers
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.